Overview Financials News + Filings IR Vault Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
|
|
Merck & Co., Inc. (MRK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/18/2023 |
PX14A6G
| Form PX14A6G - Notice of exempt solicitation submitted by non-management: |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"4.050% Notes due 2028 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2028 Notes",
"4.300% Notes due 2030 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2030 Notes",
"4.500% Notes due 2033 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2033 Notes",
"4.900% Notes due 2044 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2044 Notes",
"5.000% Notes due 2053 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2053 Notes",
"5.150% Notes due 2063 Officers’ Certificate of the Company dated May 17, 2023, including form of the 2063 Notes",
"Opinion and Consent of Jennifer Zachary, Esq., Executive Vice President and General Counsel of the Company" |
|
| 05/10/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
PX14A6G
| Form PX14A6G - Notice of exempt solicitation submitted by non-management: |
| 04/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/03/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/03/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9% stake in Merck & Co. Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results",
"MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP Table 1a 2022 2021 % Change 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year 4Q Full Year Sales $ 15,901 $ 14,593 $ 14,959 $ 13,830 $ 59,283 $ 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 2 % 22 % Costs, Expenses and Other Cost of sales 5,380 4,216 3,934 3,881 17,411 3,199 3,104 3,450 3,873 13,626 0 % 28 % Selling, general and administrative 2,323 2,512 2,520 2,687 10,042 2,187 2,281 2,336 2,830 9,634 -5 % 4 % Research and development 2,576 2,798 4,399 3,775 13,548 2,412 4,321 2,445 3,068 12,245 23 % 11 % Restructuring costs 53 142 94 49 337 297 82 107 174 661 -72 % -49 % Other expense, net 708 438 429 1,501 -77 % * Income from Continuing Operations Before Taxes 4,861 4,487 3,583 3,513 16,444 2,987 1,717 5,266 3,909 13,879 -10 % 18 % In..." |
|
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/27/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/28/2022 |
8-K
| Quarterly results |
| 06/15/2022 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
| 06/15/2022 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
| 06/15/2022 |
11-K
| Form 11-K - Annual report of employee stock purchase, savings and similar plans: |
| 05/26/2022 |
8-K
| Quarterly results |
|
|
|